Slide 1: Fiscal Third Quarter 2025 Financial Results
Conference Call 1 Fiscal Third Quarter 2025 Financial Results Au g u s t 5 , 2 0 2 5 1 © 2025 Azenta, Inc. • All rights reserved
Slide 2: Safe Harbor Statement
Safe Harbor Statement “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that co
Slide 3: Azenta Life Sciences Q3 2025 Financial Overview
Azenta Life Sciences Q3 2025 Financial Overview Continuing Operations – Quarter Ended June 30, 2025 Balance Sheet and Q3’25 Revenue (YoY) Profitability Capital Allocation • Revenue of $144M, flat YoY growth • Non-GAAP EPS of $0.19 • Strong balance sheet with cash on a reported and down (2%) on an ba
Slide 4: Azenta Operating Performance
Azenta Operating Performance Continuing Operations – Quarter Ended June 30, 2025 Total Azenta Organic Growth Q1’24 Revenue Growth (YtY) Non-GAAP $ millions $ millions except EPS and percentages Q3'24 Q3'25 YtY Revenue 144 144 (0%) Azenta | Q3'25 QTD Gross profit 67 70 4% Q1'23 Q1'24 YtY Q3'24 Q3'25
Slide 5: Q3 2025 Revenue Summary
Q3 2025 Revenue Summary Organic unless otherwise noted Sample Management Solutions Sample Management Solutions 54% (“SMS”) • LSD growth in Sample Repository Solutions • $78 million • (4%) % YoY reported • Core Products declined LDD due to softness • (6%) YoY organic in Cryo Stores and timing delays
Slide 6: Summary Consolidated Balance Sheet
Summary Consolidated Balance Sheet Quarter Ended June 30, 2025 Balance Sheet Q1’24 Revenue Growth (YtY) Highlights Mar Jun $ millions 2025 2025 QtQ Cash, restricted cash, short term marketable securities 330 321 (9) • B Medical assetsQ1'23 and liabilities are presented Q1'24 YtY as Accounts receivab
Slide 7: Summary Consolidated Cash Flow
Summary Consolidated Cash Flow Quarter Ended June 30, 2025 Cash Flow Q1’24 Revenue Growth (YtY) Highlights $ millions Q3'25 • $565M of cash, cash Q1'23equivalents, Q1'24 restrictedYtY cash Cash, restricted cash and marketable securities - Beginning 540 and marketable securities, including $15M in Ne
Slide 8: Fiscal Year 2025 Guidance
Fiscal Year 2025 Guidance Continuing Operations Guidance, excluding B Medical Systems Metric FY’2025 Organic Growth: 3% to 5% YoY Revenue Multiomics: MSD vs LSD prior Sample Management Solutions: LSD vs MSD prior Adjusted 300bps of Adjusted EBITDA margin expansion EBITDA Other Interest Income:$16M -
Slide 9: Appendix
Appendix 9 9 © 2025 Azenta, Inc. • All rights reserved
Slide 10: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation Continuing Operations – Total Azenta $ millions except EPS and percentages $ millions, except EPS Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Revenue 141.7 136.4 144.3 150.8 573.2 147.5 143.4 143.9 GAAP gross profit 61.7 60.7 65.5 69.6 257.5 68.7 65.9
Slide 11: GAAP to Non-GAAP Reconciliation – Segments
GAAP to Non-GAAP Reconciliation Continuing Operations – Segments $ millions except percentages Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Multiomics Revenue 62.7 62.2 63.6 66.0 254.6 66.3 63.5 66.2 Gross profit 28.5 27.7 29.2 30.0 115.4 30.6 27.6 27.3 Gross profit margin 45.4% 44.6
Slide 12: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions except percentages Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Net income (15.7) (136.9) (6.6) (5.0) (164.2) (13.3) (40.5) (52.8) (Income) Loss from discontinued operations, net of tax 8.5 120.7 6.4 4.9 14
Slide 13: Calculation of Non-GAAP Organic Revenue
Calculation of Non-GAAP Organic Revenue Continuing Operations Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Revenue 4% 2% 4% 6% 4% 5% (0%) Acquisitions/divestitures (1%) 0% 0% 0% 0% 0% 0% Currency exchange rates (1%) 0% 1% (0%) (0%) 1% (2%) Organic revenue 2% 3% 4% 5% 4% 6% (2%) Q1 FY24 Q2